Share on StockTwits
 

Achillion Pharmaceuticals (NASDAQ:ACHN)‘s stock had its “neutral” rating reiterated by stock analysts at UBS AG in a report issued on Monday, ARN reports. They currently have a $3.50 price objective on the stock, down from their previous price objective of $6.50. UBS AG’s price target would indicate a potential upside of 0.86% from the company’s current price.

ACHN has been the subject of a number of other recent research reports. Analysts at Zacks upgraded shares of Achillion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note to investors on Wednesday, January 1st. They now have a $3.60 price target on the stock. Analysts at Credit Suisse downgraded shares of Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, October 16th. They now have a $4.00 price target on the stock, down previously from $11.00. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and one has given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $5.23.

In other Achillion Pharmaceuticals news, major shareholder Qvt Associates Gp Llc sold 170,239 shares of Achillion Pharmaceuticals stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $3.34, for a total value of $568,598.26. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its earnings data on Tuesday, November 12th. The company reported ($0.14) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.20) by $0.06. During the same quarter in the prior year, the company posted ($0.20) earnings per share.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.